SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• MajesTEC-1 (MMY1001) is a phase 1/2, multicohort study evaluating the safety and efficacy of TECVAYLI in patients with relapsed or refractory multiple myeloma (RRMM).^1,2
  • Per protocol, patients with known active central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma (MM), were excluded from enrollment.²
• A search of the scientific literature retrieved limited information from 2 congress posters presented at the European Hematology Association (EHA) 2024 meeting, describing clinical outcomes of bispecific antibody treatment in patients with MM and CNS involvement:
  • Mersi J, Eisele F, Zhou X, et al. The role of bispecific antibodies and CAR T cells in the treatment of multiple myeloma with central nervous system involvement. Poster presented at: European Hematology Association (EHA) 2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.
  • Lachenal F, Gerome T, Chalopin T, et al. Effectiveness and safety of bispecific antibodies targeting BCMA and CD3 in patients with central nervous system multiple myeloma (CNS-MM): IFM 2023-06, a retrospective cohort study. Poster presented at: European Hematology Association (EHA) 2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.

literature search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 23 July 2024.